MD Anderson welcomes V. Craig Jordan, Ph.D., one of the world’s preeminent experts in breast cancer research and treatment. Jordan is considered the “father of tamoxifen,” the drug that’s saved countless lives.
Jordan, who was born in New Braunfels, Texas, and raised in England, reinvented a failed contraceptive, created in the 1960s to block estrogen, as a breast cancer treatment. Jordan developed the strategy of long-term adjuvant tamoxifen therapy and deciphered the properties of a new group of medicines called selective estrogen receptor modulators. He also discovered the preventive abilities of tamoxifen and raloxifene, both Food and Drug Administration approved for reducing breast cancer incidence in high-risk women.
As a professor in Breast Medical Oncology and Molecular and Cellular Oncology, Jordan will focus on the new biology of estrogen-induced cell death. He joined MD Anderson in October.
Jordan previously was scientific director of the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C. He also served as the Vincent T. Lombardi Chair of Translational Cancer Research and vice chairman of the Department of Oncology and professor of oncology and pharmacology at Georgetown University’s Medical School.